BTAI (BioXcel Therapeutics, Inc.) Stock Market Reviews

crown

search

Read and share opinions on BTAI (BioXcel Therapeutics, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock mark

BTAI

BioXcel Therapeutics, Inc.

clarify Biotechnology

bookmark Healthcare

public United States

Sell Neutral Buy

Latest News

BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates
Nov 12, 2025
BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer’s Disease
Nov 12, 2025
BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes
Oct 14, 2025
BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation
Oct 13, 2025
BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements
Sep 18, 2025
BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Sep 4, 2025
BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025
Aug 26, 2025
BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
Aug 19, 2025
BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia
Aug 18, 2025
BioXcel Therapeutics Second Quarter 2025 Earnings: Misses Expectations
Aug 13, 2025
BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. “HCW@Home” Series
Aug 13, 2025
BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Lags Revenue Estimates
Aug 12, 2025
BioXcel Therapeutics to Participate in Canaccord Genuity 45th Annual Growth Conference
Aug 11, 2025
BioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of Dexmedetomidine (the active ingredient in BXCL-501) on Stress-Mediated Behaviors in Non-clinical Studies
Aug 6, 2025

Reviews